Ind-Swift Laboratories is contemplating to raise funds to expand the existing manufacturing capacities including the setting up a new multi product manufacturing blocks, debottlenecking and long term working capital requirements.
At present, the company is ready with the commercial launch of the certain products developed by its In-house state of the art Research and Development (R&D) centre. These products are, Atorvastatin with a global market size of $12 billion, Fexofenadine with a global market size of $1.5 billion, Rosuvastatin with a global market size of $6 billion, Temozolamide with a global market size of $900 million and Ivabradine with a global market size of $154 million.
Meanwhile, the company is eyeing the market size in the range of more than 10% to 20% of the generic market of these drugs in coming years upon commercial launch. Moreover, the funds raised will enable the company to have capacities to manufacture these products at commercial pace and rise to the next EBIDTA level.
The company is also eyeing for a strategic investors for which it has accorded mandate to a leading MNC Ernst & Young ( EY) to conduct the due diligence process for the prospective foreign investors who have shown interest in the company .
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1522.40 |
Dr. Reddys Lab | 6405.75 |
Cipla | 1482.00 |
Zydus Lifesciences | 1074.35 |
Lupin | 1625.00 |
View more.. |